尼可地尔联合瑞舒伐他汀对经皮冠状动脉介入治疗患者的心肌保护作用

发布时间：2018-08-19 12:02

【摘要】：目的观察尼可地尔联合瑞舒伐他汀对冠状动脉介入治疗患者心肌保护作用。方法将68例择期进行经皮冠状动脉介入治疗术(PCI)的冠心病患者随机分为对照组36例和试验组32例。对照组术前予瑞舒伐他汀10 mg,qd,共3 d;试验组在对照组的基础上,术前加用尼可地尔5 mg,tid,共3 d。比较2组患者临床疗效、PCI术前和术后24,48 h血清高敏肌钙蛋白T(hs-cTnT)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的显效率分别为78.13%(25例/32例)和52.78%(19例/36例),差异有统计学意义(P0.05)。PCI术前,试验组和对照组hs-cTnT水平分别为(36.56±15.35),(30.29±13.67)pg·mL~(-1),hs-CRP分别为(3.67±1.24),(3.53±1.32)mg·L~(-1),TNF-α分别为(6.54±2.42),(6.76±2.15)pg·mL~(-1),IL-10分别为(6.87±1.92),(7.02±1.85)pg·mL~(-1)。PCI术后24 h,试验组和对照组hs-cTnT水平分别为(71.25±17.87),(82.65±18.34)pg·mL~(-1),hs-CRP分别为(9.48±2.35),(13.56±3.52)mg·L~(-1),TNF-α分别为(8.72±2.26),(10.65±3.16)pg·mL~(-1),IL-10分别为(13.55±4.51),(11.21±3.54)pg·mL~(-1);术后48 h试验组和对照组hs-cTnT水平分别为(60.56±15.64),(73.54±16.51)pg·mL~(-1),hs-CRP分别为(6.62±1.98),(10.24±2.84)mg·L~(-1),TNF-α分别为(7.56±1.86),(8.86±1.95)pg·mL~(-1),IL-10分别为(11.16±3.28),(9.76±3.11)pg·mL~(-1),术后24 h与术后48 h比较,差异均有统计学意义(均P0.05)。试验组及对照组均没有出现明显的药物不良反应。结论 PCI术前尼可地尔联合瑞舒伐他汀可以降低炎性因子,提高IL-10,减轻PCI心肌损伤,安全性好。
[Abstract]:Objective to observe the myocardial protective effect of nicoranil combined with resuvastatin on patients with coronary intervention. Methods Sixty-eight patients with (PCI) undergoing percutaneous coronary intervention were randomly divided into control group (n = 36) and trial group (n = 32). The control group was treated with resuvastatin 10 mg / g QD for 3 days, and the control group was treated with nicorandil 5 mg / d for 3 days. The clinical effects of the two groups were compared. The serum levels of Gao Min troponin T (hs-cTnT), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor- 伪 (TNF- 伪), interleukin-10 (IL-10) and adverse drug reactions were compared between the two groups. Results after treatment, the effective rates of the experimental group and the control group were 78.13% (25 / 32) and 52.78% (19 / 36), respectively. The difference was statistically significant (P0.05). 璇曢獙缁勫拰瀵圭収缁刪s-cTnT姘村钩鍒嗗埆涓，

本文编号：2191596